Home › News › Quality / GMP

Haemonetics Receives CE Mark Certification for VASCADE MVP XL Vascular Closure System

Haemonetics Receives CE Mark Certification for VASCADE MVP XL Vascular Closure System

 

Haemonetics Corporation has received CE Mark certification under the European Union Medical Device Regulation (EU-MDR) for its VASCADE MVP XL venous vascular closure system, allowing the company to expand its availability in the European Union and other markets that recognise CE marking.

The system is designed for the closure of femoral venous access sites following catheter-based procedures using procedural sheaths with an inner diameter of 10–12F and a maximum outer diameter of 15F. It is intended for procedures involving single or multiple access sites in one or both limbs.

According to the company, the VASCADE MVP XL system is designed to reduce time to haemostasis, ambulation, total post-procedure time and discharge eligibility compared with conventional closure methods. It also supports the potential for same-day discharge in eligible patients.

The device uses 58 percent more collagen and a 9 percent larger disc than the VASCADE MVP system. It is designed for larger-bore venous access procedures, including cryoablation, Pulsed Field Ablation (PFA) and Left Atrial Appendage Closure (LAAC).

The first European procedures using the VASCADE MVP XL system were performed in October at medical centres in Germany, Italy and the United Kingdom. The procedures were conducted by Prof. Christian H. Heeger at Asklepios Clinic Altona in Hamburg, Prof. Claudio Tondo at Centro Cardiologico Monzino in Milan, and Dr. Riyaz A. Kaba at Cromwell Hospital in London.

Haemonetics' vascular closure portfolio also includes the VASCADE vascular closure system, designed for small-bore femoral arterial and venous closure using standard 5–6/7F procedural sheaths, and the VASCADE MVP system, designed for mid-bore multi-access femoral venous closure using 6–12F inner-diameter procedural sheaths.

Both systems are CE marked under the EU-MDR and use collapsible disc technology and a resorbable collagen plug to achieve haemostasis following catheter-based procedures.

More news about: quality / gmp | Published by News Bureau | November - 19 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members